Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
In clinical trials, treatment proved more effective than other therapies evaluated
The partners also aim to expand their work to Latin America for the first time
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
Subscribe To Our Newsletter & Stay Updated
